---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-24-000153"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:08:51.945750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M

## Summary
- Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.
- Net loss decreased 4% to $18M; adjusted EBITDA improved 305% to $13M, fifth consecutive positive quarter.
- FY 2024 adjusted EBITDA guidance raised to $37-40M (from $33-37M); revenue guidance unchanged at $655-667M.
- Board appointed Felicia Williams; initial equity award ~$140,000 vesting June 1, 2025.

## SEC filing metadata
- accession: 0001077183-24-000153
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/neo-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-24-000153
- JSON: https://secwatch.observer/filing/0001077183-24-000153.json
- Plain text: https://secwatch.observer/filing/0001077183-24-000153.txt

## Key facts
- Executive change
  Felicia Williams was appointed as member of the Board at NEOGENOMICS INC.
  - Action: appointed
  - Role: member of the Board
  source text: On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.